Track market-moving stories before they get noisy

Allspring Global Investments Holdings LLC increased its position in Revvity Inc. (NYSE: RVTY) by 127.0% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 1,751,612 shares of the company's stock after acquiring an additional 980,142 shares during the quarter. Allspring Global Investments Holdings

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining.

Revvity launches Signals BioDesign, a cloud-based cloning platform to streamline biotech R&D workflows and boost collaboration in biologics development.

Posted by Defense World Staff on Apr 19th, 2026

Sumitomo Mitsui Trust Group Inc. trimmed its position in Revvity Inc. (NYSE:RVTY – Free Report) by 86.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,730 shares of the company’s stock after selling 235,296 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Revvity were worth $3,457,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RVTY. CYBER HORNET ETFs LLC acquired a new stake in Revvity in the second quarter worth about $32,000. Cromwell Holdings LLC increased its position in Revvity by 141.4% in the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after purchasing an additional 198 shares during the period. MUFG Securities EMEA plc acquired a new stake in Revvity in the second quarter worth about $34,000. Headlands Technologies LLC acquired a new stake in Revvity in the second quarter worth about $49,000. Finally, Smartleaf Asset Management LLC increased its position in Revvity by 56.8% in the third quarter. Smartleaf Asset Management LLC now owns 690 shares of the company’s stock worth $58,000 after purchasing an additional 250 shares during the period. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Price Performance Shares of RVTY opened at $94.00 on Friday. The company has a current ratio of 1.68, a quick ratio of 1.40 and a debt-to-equity ratio of 0.36. Revvity Inc. has a 1 year low of $81.36 and a 1 year high of $118.30. The stock has a market cap of $10.51 billion, a P/E ratio of 45.19, a price-to-earnings-growth ratio of 1.90 and a beta of 1.13. The stock’s 50-day moving average price is $92.22 and its two-hundred day moving average price is $96.98.

Revvity (NYSE:RVTY – Get Free Report) last issued its earnings results on Monday, February 2nd. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Revvity had a return on equity of 7.92% and a net margin of 8.45%.The firm had revenue of $772.06 million for the quarter, compared to analysts’ expectations of $759.81 million. During the same quarter last year, the business earned $1.42 earnings per share. The company’s revenue was up 5.9% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. On average, equities analysts predict that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Stockholders of record on Friday, April 17th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Friday, April 17th. Revvity’s payout ratio is 13.46%.

Wall Street Analyst Weigh In A number of equities analysts have issued reports on RVTY shares. TD Cowen restated a “hold” rating on shares of Revvity in a report on Tuesday, February 3rd. Evercore raised their target price on Revvity from $112.00 to $118.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Jefferies Financial Group raised their target price on Revvity from $100.00 to $105.00 and gave the stock a “hold” rating in a report on Monday, February 2nd. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Barclays restated an “equal weight” rating and set a $95.00 target price (down from $118.00) on shares of Revvity in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $110.17.

Check Out Our Latest Research Report on Revvity

Revvity Company Profile (Free Report)

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

Featured Articles Five stocks we like better than Revvity

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBayforest Capital Ltd Boosts Stake in First Hawaiian, Inc. $FHB

NEXT HEADLINE »Sumitomo Mitsui Trust Group Inc. Decreases Stake in SPDR Portfolio S&P 400 Mid Cap ETF $SPMD

RVTY heads into Q1 earnings with Diagnostics strength and Life Sciences stabilization, but China pressures and weak academic demand may temper near-term growth.

Revvity (RVTY - Free Report) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +4.10%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.63 per share when it actually produced earnings of $1.7, delivering a surprise of +4.29%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Revvity, which belongs to the Zacks Medical Services industry, posted revenues of $711.12 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.85%. This compares to year-ago revenues of $664.76 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Revvity shares have lost about 10.6% since the beginning of the year versus the S&P 500's gain of 5.2%.

What's Next for Revvity?While Revvity has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Revvity was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.28 on $742.53 million in revenues for the coming quarter and $5.39 on $2.98 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Ascend Wellness Holdings, Inc. (AAWH - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 13.

This company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of -44.4%. The consensus EPS estimate for the quarter has been revised 3.9% higher over the last 30 days to the current level.

Ascend Wellness Holdings, Inc.'s revenues are expected to be $114.2 million, down 10.8% from the year-ago quarter.

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company's FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single pla.

Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BridgeBio remains a compelling Buy, driven by Attruby's strong U.S. launch and favorable competitive dynamics following Pfizer's patent settlements. Attruby's peak annual sales are conservatively modeled at $2.2B, with sensitivity up to $4B, underpinned by a protected branded market through mid-2031. BBIO's late-stage pipeline—infigratinib, encaleret, and BBP-418—offers potential for additional blockbusters, supporting long-term value beyond Attruby.

May 04, 2026 07:30 ET  | Source: BridgeBio Pharma, Inc.

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, including one late-breaking oral presentation, of new data from the Phase 3 ATTRibute-CM study in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology (ESC-HF), taking place in Barcelona, Spain on May 9-12, 2026.

Bayer, BridgeBio’s exclusive European licensing partner of acoramidis, will be presenting a late-breaking oral presentation on data from ATTRibute-CM related to acoramidis’ impact on the outcome of outpatient worsening heart failure.

Acoramidis is approved as Attruby® by the U.S. FDA and is approved as BEYONTTRA® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, and the UK Medicines and Healthcare Products Regulatory Agency with all labels specifying near-complete stabilization of TTR.

Late-Breaking Oral Presentation:
Effect of Acoramidis on Temporal Variability of Serum Transthyretin and its Influence on Outcomes: Insights from the ATTRibute-CM Trial
Presenter: Senthil Selvaraj, M.D., Duke University School of Medicine, U.S.
Date: Monday, May 11 at 3:30 pm CEST

Moderated ePoster:
Anchored Matching-Adjusted Indirect Comparison of Acoramidis (ATTRibute-CM) Versus Tafamidis (ATTR-ACT) for Risk of Cardiovascular-Related Hospitalization, All-Cause Mortality and Safety in ATTR-CM
Presenter: Emer Joyce, M.D., Ph.D., The Mater Misericordiae University Hospital, IE
Date: Sunday, May 10 at 3:30 pm CEST

Acoramidis Treatment Attenuates the Rise in NT-proBNP from Baseline to Month 30 Compared to Placebo Across all Subgroups
Presenter: Marianna Fontana, M.D., University College London, UK
Date: Monday, May 10 at 3:30 pm CEST

Posters:
Consistent Benefit on Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) with Acoramidis Treatment Compared with Placebo Across Participant Subgroups in ATTRibute-CM
Presenter: Marianna Fontana, M.D., University College London, UK
Date: Saturday, May 9 at 12:56 pm CEST

Effect of Acoramidis on Improvement or Maintenance of Heart Failure-Related Health Status as Assessed by KCCQ-OS Score in ATTRibute-CM
Presenter: Charles Sherrod, M.D., Saint Luke’s Health System, Kansas City, U.S.
Date: Saturday, May 9 at 3:36 pm CEST

About Attruby™ (acoramidis)

INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
[email protected]   
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected] 

May 06, 2026 07:30 ET  | Source: BridgeBio Pharma, Inc.

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including:

- By Month 1, numerically fewer cumulative cardiovascular events, including CVM or recurrent CVH, were observed with acoramidis compared to placebo
- A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30
- A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30

- Acoramidis is the first and only approved ATTR-CM treatment in the U.S., EU, UK, Switzerland, Japan, and Brazil that all have a label specifying near-complete stabilization (≥90%)

PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization for acoramidis, under the brand name BEYONTTRA, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered near-complete (≥90%) transthyretin (TTR) stabilizer.

“The ATTRibute-CM results represent a major advance for patients with ATTR-CM, who often face an earlier and more aggressive course of disease,” said Fábio Fernandes, M.D., Ph.D., Director at the Heart Institute of the Clinical Hospital of the University of São Paulo Medical School (HCFMUSP), and investigator in the trial. “For too long, this community has lived with limited options and delayed recognition of their condition. Seeing a therapy like acoramidis deliver significant reductions in cardiovascular-related hospitalizations, improvements in survival, and preservation of functional capacity and quality of life is profoundly encouraging. These results signal a transformative shift in how we can care for patients across Brazil.”

The approval in Brazil is based on results of the pivotal ATTRibute-CM Phase 3 study of acoramidis, which showed clear benefits on cardiovascular outcomes. ATTRibute-CM evaluated the efficacy and safety of acoramidis in 632 participants with symptomatic ATTR-CM, associated with either wild-type or variant TTR who were randomized 2:1 to receive acoramidis or placebo for 30 months. The study met its primary clinical endpoints at Month 30 by significantly reducing cardiovascular-related hospitalization, improving survival, and preserving functional capacity and quality of life for patients.

“The ANVISA approval of BEYONTTRA marks an important step forward for Brazilian patients living with ATTR-CM. It is a particularly meaningful advance for patients living in Brazil who have long faced limited options for this progressive, life-threatening disease,” said Jonathan Fox, M.D., Chief Medical Officer of BridgeBio Cardiorenal. “This authorization brings new hope to communities where ATTR-CM is increasingly recognized. This also reflects our commitment to ensuring that as many patients as possible in as many countries as possible have access to transformative care. We are profoundly grateful to the patients, families, investigators, and clinical partners whose courage and partnership made this milestone possible.”

Acoramidis was approved as Attruby® by the U.S. FDA in November 2024 and was approved as BEYONTTRA by the European Commission in February 2025, the Japanese Ministry of Health, Labour, and Welfare (MHLW) Agency in March 2025, and the UK Medicines and Healthcare Products Regulatory Agency in April 2025 with all labels specifying near-complete stabilization of TTR. Acoramidis is also currently under review by other global regulatory agencies.

BridgeBio will work in partnership with Biopas, a Swixx BioPharma company with an established pharmaceutical commercialization platform in Latin America, to commercialize BEYONTTRA in Brazil. Commercialization efforts are expected to begin in the second half of 2026, ensuring that Brazilian patients with ATTR-CM gain access to acoramidis as quickly as possible.

About BEYONTTRA
BEYONTTRA is an orally administered near-complete (≥90%) stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Full prescribing information for Brazil will be available through ANVISA.

About Attruby® (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio Pharma, Inc. (BridgeBio; Nasdaq: BBIO) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions, or the negative of these terms or other comparable terminology. These words are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.These forward-looking statements, including statements regarding the potential clinical and commercial benefits of acoramidis and the potential outcomes; expected timing of commercialization efforts; potential patient access to acoramidis; and expected timing and outcome of regulatory reviews and approvals by other global regulatory agencies, are based on the information currently available to BridgeBio and on assumptions BridgeBio has made. Although BridgeBio believes that its plans, intentions, expectations, and strategies as reflected in or suggested by these forward-looking statements are reasonable, BridgeBio can give no assurance that such plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties, and assumptions, including, but not limited to, risks associated with the continued development and commercialization of acoramidis; the occurrence of adverse safety events; the ability to maintain regulatory approvals; the need for additional clinical data or analyses requested by regulatory authorities; whether future results will be consistent with prior clinical findings; BridgeBio’s reliance on third parties, including commercialization partners, and their ability to execute on commercialization and distribution activities; manufacturing, supply continuity, and quality obligations; pricing, reimbursement, market access, and adoption in Brazil and other markets; and the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, and increasing rates of inflation and changing interest rates, on BridgeBio’s business operations and expectations. Additional risks are set forth in the “Risk Factors” section of BridgeBio’s most recent Annual Report on Form 10-K and other subsequent filings with the U.S. Securities and Exchange Commission. Except as required by applicable law, BridgeBio assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
[email protected]  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]

PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the first quarter ended March 31, 2026, and provided an update on Attruby's commercial progress.

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

© sanjeri / E+ via Getty Images

BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with Citi’s simultaneous Buy initiation Buy ratings on peer biotechs Alnylam, Ascendis Pharma, BioMarin, Cytokinetics, and of Ionis Pharmaceuticals (NASDAQ:IONS), making the BBIO Neutral a cautious outlier. For prudent investors, the rating frames a real tension between commercial momentum and competitive risk.

Ticker Company Firm Action Old Rating New Rating Old Target New Target BBIO BridgeBio Pharma Citi Initiation N/A Neutral N/A Not disclosed BridgeBio’s lead drug Attruby (acoramidis) is tracking a steep commercial ramp, alongside $500 million share repurchase program and three additional NDAs planned for 2026. Citi’s caution stands against broader Wall Street sentiment that includes 22 buy ratings on BBIO stock.

The Analyst’s Case Citi’s Neutral rating reflects a balanced view of BridgeBio’s cardiomyopathy story. The bull case centers on acoramidis’s differentiated mechanism of action, a large and growing ATTR-CM patient population, broader pipeline assets, and attractive risk/reward relative to other gene-targeted biotechs.

The bear case is equally concrete. BridgeBio’s Attruby competes head-to-head with Pfizer’s established tafamidis (Vyndaqel/Vyndamax) franchise, while commercial ramp execution risk, R&D burn, and pipeline assets early in development weigh on the setup. That Citi initiated Ionis Pharmaceuticals at Buy the same day sharpens the signal: the firm sees opportunity in gene-targeted biotech, yet drew a line at BridgeBio’s competitive setup.

Company Snapshot BridgeBio is a clinical-stage biopharmaceutical company focused on genetic diseases and cancers driven by Mendelian disease drivers. Lead product Attruby won U.S. approval for ATTR-CM in late 2024 and posted Q1 2026 U.S. net product revenue of $180.6 million, versus $36.74 million a year earlier. Total revenue rose year over year.

BridgeBio closed the quarter with $940.19 million in cash and a market cap near $13.03 billion. The pipeline includes upcoming NDAs for BBP-418 in LGMD2I/R9, encaleret in ADH1, and oral infigratinib in achondroplasia, each potentially eligible for priority review.

Why the Move Matters Now The Neutral call arrives against a broadly bullish analyst tape. Pfizer (NYSE:PFE) still generated $1.688 billion in Q4 2025 Vyndaqel-family revenue, up 9% year over year, underscoring how much share Attruby must capture to justify BBIO’s valuation.

BBIO stock has been under pressure recently, with shares down 15% over the past month, even as the one-year return remains up 94%. Citi’s initiation lands in a more skeptical tape than the buy-rated chorus suggests.

What It Means for Your Portfolio For prudent investors, the Citi Neutral initiation is a reminder that strong launch metrics and competitive risk coexist. BridgeBio’s commercial trajectory looks healthy, yet Pfizer’s incumbency and Ionis’s eplontersen CARDIO-TTRansform readout expected later 2026 could pressure the long-term ATTR-CM share thesis.

BBIO stock may suit investors comfortable with biotech volatility and execution risk. Moderate position sizing, rather than aggressive accumulation, fits the balanced framing Citi is signaling. Keep an eye on BridgeBio through three planned 2026 NDAs and competitive cardiomyopathy data flow.

First quarter send volume up 37% and revenue up 25% year over year
First quarter net income of $49.1 million up 332% and Adjusted EBITDA of $101.6 million up 74% year over year

SEATTLE, May 06, 2026 (GLOBE NEWSWIRE) -- Remitly Global, Inc. (NASDAQ: RELY), a trusted provider of financial services that transcend borders, reported results for the first quarter ended March 31, 2026.

“We delivered an exceptional Q1, achieving record revenue and Adjusted EBITDA,” said Sebastian Gunningham, Chief Executive Officer, Remitly. “Outperformance across key corridors and an increasing pace of product innovation are contributing to strong momentum in the business. The accelerated growth in quarterly active users is evidence of the continued trust and confidence customers place in Remitly. At the same time, disciplined cost management, scale benefits, and AI-driven efficiencies are delivering strong operating leverage.”

First Quarter 2026 Highlights and Key Operating Data
(All comparisons relative to the first quarter of 2025)

Active customers increased to 9.6 million, from 8.0 million, up 20%.Send volume increased to $22.1 billion, from $16.2 billion, up 37%.Revenue totaled $452.8 million, compared to $361.6 million, up 25%.Net income was $49.1 million, compared to $11.4 million, up 332%.Adjusted EBITDA was $101.6 million, compared to $58.4 million, up 74%. 2026 Financial Outlook
For fiscal year 2026, Remitly currently expects:

Total revenue in the range of $1.960 billion to $1.975 billion, representing a growth rate of 20 to 21% year over year.Year over year growth in net income for 2026 and Adjusted EBITDA to be in the range of $370 million to $385 million. For the second quarter of 2026, Remitly currently expects:

Total revenue in the range of $483 million to $485 million, representing a growth rate of 17% to 18% year over year.Year over year growth in net income for the second quarter of 2026 and Adjusted EBITDA to be in the range of $86 million to $88 million. Reconciliation of GAAP to Non-GAAP Financial Measures
A reconciliation of accounting principles generally accepted in the United States of America (“GAAP”) to non-GAAP financial measures has been provided in the financial statement tables included in this earnings release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.” We have not provided a quantitative reconciliation of forecasted Adjusted EBITDA to forecasted GAAP net income (loss) or to forecasted GAAP income (loss) before income taxes within this earnings release because we cannot, without unreasonable effort, calculate certain reconciling items with confidence due to the variability, complexity, and limited visibility of the adjusting items that would be excluded from forecasted Adjusted EBITDA. These items include, but are not limited to, income taxes, stock-based compensation expense, and payroll taxes related to stock-based compensation expense, which are directly impacted by unpredictable fluctuations in the market price of our common stock. The variability of these items could have a significant impact on our future GAAP financial results.

Note: All percentage changes described within this press release are calculated using amounts in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”), for which revenue and active customers are presented in thousands and send volume is presented in millions. Rounding differences may occur when individually calculating percentages or totals from rounded amounts included within the press release body as compared to the amounts included within the Company’s SEC filings.

Webcast Information
Remitly will host a webcast at 5:00 p.m. Eastern Time on Wednesday, May 6, 2026, to discuss its first quarter 2026 financial results. The live webcast and investor presentation will be accessible on Remitly’s website at https://ir.remitly.com. A webcast replay will be available on our website at https://ir.remitly.com following the live event.

We have used, and intend to continue to use, the Investor Relations section of our website at https://ir.remitly.com as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD.

Non-GAAP Financial Measures
Some of the financial information and data contained in this earnings release, such as Adjusted EBITDA, free cash flow, and non-GAAP operating expenses, have not been prepared in accordance with GAAP.

We regularly review our key business metrics and non-GAAP financial measures to evaluate our performance, identify trends affecting our business, prepare financial projections, and make strategic decisions. We believe that these key business metrics and non-GAAP financial measures provide meaningful supplemental information for management and investors in assessing our historical and future operating performance. Adjusted EBITDA and non-GAAP operating expenses are key output measures used by our management to evaluate our operating performance, inform future operating plans, and make strategic long-term decisions, including those relating to operating expenses and the allocation of internal resources. We believe that the use of Adjusted EBITDA and non-GAAP operating expenses provides additional tools to assess operational performance and trends in, and in comparing our financial measures with, other similar companies, many of which present similar non-GAAP financial measures to investors. Free cash flow is a key measure used by our management to understand the strength of our liquidity and available cash, and we believe that the presentation of this measure is useful because we are focused on growing our free cash flow generation over time. Free cash flow is not intended to represent the total increase or decrease in our cash balance for the period. Our non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial measures determined in accordance with GAAP. Because of the limitations of non-GAAP financial measures, you should consider the non-GAAP financial measures presented herein in conjunction with our financial statements and the related notes thereto. Please refer to the non-GAAP reconciliations in this press release for a reconciliation of these non-GAAP financial measures to the most comparable financial measure prepared in accordance with GAAP.

We calculate Adjusted EBITDA as net income (loss) adjusted by (i) interest (income) expense, net; (ii) provision for income taxes; (iii) noncash charges of depreciation and amortization; (iv) other (income) expense, net; (v) noncash charges associated with our donation of common stock in connection with our Pledge 1% commitment; (vi) noncash stock-based compensation expense, net; (vii) payroll taxes related to stock-based compensation expense, net; and (viii) certain restructuring and other costs.

We calculate free cash flow as net cash provided by operating activities, adjusted for capitalized expenditures that include purchases of property and equipment and capitalized internal-use software.

We calculate non-GAAP operating expenses as our GAAP operating expenses adjusted by (i) noncash stock-based compensation expense, net; (ii) payroll taxes related to stock-based compensation expense, net; (iii) noncash charges associated with our donation of common stock in connection with our Pledge 1% commitment; as well as (iv) certain restructuring and other costs.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. These statements include, but are not limited to, statements regarding future events or our future results of operations and financial position, including our fiscal year and second quarter 2026 financial outlook, including forecasted fiscal year and second quarter 2026 revenue, net income (loss), and Adjusted EBITDA, anticipated future expenses and investments, expectations relating to certain of our key financial and operating metrics, our business strategy and plans, our growth, our position and potential opportunities, and our objectives for future operations. The words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “likely,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms are intended to identify forward-looking statements. Forward-looking statements are based on management’s expectations, assumptions, and projections based on information available at the time the statements were made. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including risks and uncertainties related to our expectations regarding our revenue, expenses, and other operating results; our ability to acquire new customers and successfully retain existing customers; our ability to continue to develop new products and services in a timely manner; our ability to sustain our profitability; our ability to maintain and expand our strategic relationships with third parties; our business plan and our ability to effectively manage our growth; anticipated trends, growth rates, and challenges in our business and in the market segments in which we operate; our ability to effectively integrate and leverage artificial intelligence and machine learning technologies; our ability to attract, integrate, and retain qualified employees, including key members of our management team; uncertainties regarding the impact of geopolitical and macroeconomic conditions, including currency fluctuations, inflation, regulatory changes (including as may be related to immigration, fiscal and tax policy, foreign trade, or foreign investment), regional and global conflicts or related government sanctions, or legislative or regulatory developments; our ability to maintain the security and availability of our solutions; our ability to maintain our money transmission licenses and other regulatory clearances or obtain new licenses and regulatory clearances; our ability to maintain and expand international operations; our expectations regarding anticipated technology needs and developments and our ability to address those needs and developments with our solutions; and our stock repurchase program, the timing and number of shares of our common stock to be repurchased, and the potential benefits thereof. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, our actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Further information on risks that could cause actual results to differ materially from forecasted results is included in our quarterly report on Form 10-Q for the quarter ended March 31, 2026, to be filed with the SEC, and within our annual report on Form 10-K for the year ended December 31, 2025, filed with the SEC, which are or will be available on our website at https://ir.remitly.com and on the SEC’s website at www.sec.gov. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

About Remitly
Remitly is a trusted provider of financial services that transcend borders. With a footprint spanning more than 175 countries, Remitly has built one of the world’s leading global money movement platforms, trusted by millions of customers. Remitly continues to evolve beyond a remittance company into a diversified, cross-border financial services provider, serving both consumers and businesses across a growing set of use cases.

Contacts

Media Inquiries:
[email protected]

Investor Relations:
[email protected]

  REMITLY GLOBAL, INC.
CondensedConsolidated Statements of Operations
(unaudited)   Three Months Ended March 31,(in thousands, except share and per share data) 2026   2025 Revenue$452,802  $361,624 Costs and expenses   Transaction expenses(1) 144,940   121,393 Customer support and operations(1) 26,811   22,573 Marketing(1) 86,362   73,349 Technology and development(1) 79,603   73,851 General and administrative(1) 55,147   52,829 Depreciation and amortization 6,199   5,396 Total costs and expenses 399,062   349,391 Income from operations 53,740   12,233 Interest income 1,653   1,787 Interest expense (2,437)  (1,299)Other (expense) income, net (881)  2,221 Income before provision for income taxes 52,075   14,942 Provision for income taxes 3,022   3,590 Net income$49,053  $11,352 Net income per share attributable to common stockholders:   Basic$0.23  $0.06 Diluted$0.23  $0.05 Weighted-average shares used in computing net income per share attributable to common stockholders:   Basic 211,032,788   201,744,601 Diluted 217,047,399   218,414,823  __________
(1) Exclusive of depreciation and amortization, shown separately.

    REMITLY GLOBAL, INC.
CondensedConsolidated Balance Sheets
(unaudited)     March 31, December 31,(in thousands) 2026   2025 Assets   Current assets   Cash and cash equivalents$649,062  $542,426 Disbursement prefunding 244,506   441,335 Customer funds receivable, net 295,792   286,455 Prepaid expenses and other current assets 58,325   45,735 Total current assets 1,247,685   1,315,951 Property and equipment, net 60,162   61,521 Operating lease right-of-use assets 9,954   12,452 Goodwill 54,940   54,940 Intangible assets, net 1,594   2,125 Other noncurrent assets, net 11,448   11,724 Total assets$1,385,783  $1,458,713 Liabilities and stockholders’ equity   Current liabilities   Accounts payable$28,784  $28,450 Customer liabilities 264,768   219,667 Short-term debt 2,844   2,821 Accrued expenses and other current liabilities 136,285   141,948 Operating lease liabilities 6,686   6,166 Total current liabilities 439,367   399,052 Operating lease liabilities, noncurrent 29,769   28,135 Long-term debt —   155,000 Other noncurrent liabilities 9,207   7,737 Total liabilities 478,343   589,924 Commitments and contingencies   Stockholders’ equity   Common stock 21   21 Additional paid-in capital 1,316,280   1,325,520 Accumulated other comprehensive income 2,434   3,596 Accumulated deficit (411,295)  (460,348)Total stockholders’ equity 907,440   868,789 Total liabilities and stockholders’ equity$1,385,783  $1,458,713    REMITLY GLOBAL, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited)   Three Months Ended March 31,(in thousands) 2026  2025(1)Cash flows from operating activities   Net income$49,053  $11,352 Adjustments to reconcile net income to net cash provided by operating activities:   Depreciation, amortization, and other 14,123   7,863 Stock-based compensation expense, net 27,536   35,792 Donation of common stock 765   959 Changes in operating assets and liabilities:   Prepaid expenses and other assets (12,723)  (6,272)Operating lease right-of-use assets 1,134   2,041 Accounts payable 4,772   22,182 Accrued expenses and other liabilities (4,896)  2,800 Operating lease liabilities 2,128   4,066 Net cash provided by operating activities 81,892   80,783 Cash flows from investing activities   Purchases of property and equipment (5,987)  (10,615)Capitalized internal-use software costs (3,199)  (2,949)Net collections (originations) from consumer receivables (4,559)  (3,348)Net cash used in investing activities (13,745)  (16,912)Cash flows from financing activities   Proceeds from exercise of stock options 417   2,392 Proceeds from issuance of common stock in connection with ESPP 6,340   5,768 Cash paid for repurchase of common stock (42,499)  — Proceeds from revolving credit facility borrowings 2,363,000   1,059,000 Repayments of revolving credit facility borrowings (2,518,000)  (1,059,000)Net change in customer funds assets and liabilities 230,803   52,120 Taxes paid related to net share settlement of equity awards (952)  (1,089)Net cash provided by financing activities 39,109   59,191 Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash (809)  2,728 Net increase in cash, cash equivalents, and restricted cash 106,447   125,790 Cash, cash equivalents, and restricted cash at beginning of period 544,299   369,817 Cash, cash equivalents, and restricted cash at end of period$650,746  $495,607 Reconciliation of cash, cash equivalents, and restricted cash   Cash and cash equivalents$649,062  $493,905 Restricted cash included in prepaid expenses and other current assets 694   632 Restricted cash included in other noncurrent assets, net 990   1,070 Total cash, cash equivalents, and restricted cash$650,746  $495,607  __________
(1) Beginning in the fourth quarter of 2025, the Company changed the presentation of certain cash activity related to customer funds assets and liabilities, which is comprised of disbursement prefunding, customer funds receivable, customer liabilities, and trade settlement liability included within the line item ‘Accrued expenses and other current liabilities’ on the Consolidated Balance Sheets. Certain components of this activity were reclassified from cash flows from operating activities to cash flows from financing activities, reflected within the line item ‘Net change in customer funds assets and liabilities.’

 REMITLY GLOBAL, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(unaudited) Reconciliation of net income (loss) to Adjusted EBITDA:     Three Months Ended March 31,(in thousands) 2026  2025 Net income$49,053 $11,352 Add:   Interest (income) expense, net 784  (488)Provision for income taxes 3,022  3,590 Depreciation and amortization 6,199  5,396 Other (income) expense, net 881  (2,221)Donation of common stock 765  959 Stock-based compensation expense, net 27,536  35,792 Payroll taxes related to stock-based compensation expense, net 1,772  3,140 Restructuring and other costs(1) 11,538  908 Adjusted EBITDA$101,550 $58,428  __________
(1) Restructuring and other costs for the three months ended March 31, 2026 and March 31, 2025 consisted primarily of non-recurring termination benefits.

 Reconciliation of cash flow from operations to free cash flow:     Three Months Ended March 31,(in thousands) 2026   2025 Net cash provided by operating activities$81,892  $80,783 Less:   Purchases of property and equipment (5,987)  (10,615)Capitalized internal-use software costs (3,199)  (2,949)Free cash flow$72,706  $67,219   Reconciliation of operating expenses to non-GAAP operating expenses:     Three Months Ended March 31,(in thousands) 2026  2025Customer support and operations$26,811 $22,573Excluding: Stock-based compensation expense, net 309  256Excluding: Payroll taxes related to stock-based compensation expense, net 5  8Excluding: Restructuring and other costs 1,644  —Non-GAAP customer support and operations$24,853 $22,309     Three Months Ended March 31,  2026  2025Marketing$86,362 $73,349Excluding: Stock-based compensation expense, net 2,173  4,127Excluding: Payroll taxes related to stock-based compensation expense, net 41  456Excluding: Restructuring and other costs 1,709  490Non-GAAP marketing$82,439 $68,276     Three Months Ended March 31,  2026  2025Technology and development$79,603 $73,851Excluding: Stock-based compensation expense, net 17,158  21,237Excluding: Payroll taxes related to stock-based compensation expense, net 1,268  1,981Excluding: Restructuring and other costs 3,463  —Non-GAAP technology and development$57,714 $50,633     Three Months Ended March 31,  2026  2025General and administrative$55,147 $52,829Excluding: Stock-based compensation expense, net 7,896  10,172Excluding: Payroll taxes related to stock-based compensation expense, net 458  695Excluding: Donation of common stock 765  959Excluding: Restructuring and other costs 4,722  418Non-GAAP general and administrative$41,306 $40,585

Remitly Global, Inc. (RELY) Q1 2026 Earnings Call Transcript

Remitly Global is rated 'buy' due to rapid business customer growth and strong adoption of Remitly Business, targeting high-value SMB senders. RELY posted Q1 '26 revenue of $453M (25% YoY growth), beating both company and analyst estimates, with active customers reaching 9.634 million. High-value sender growth (73% in Q1 '26) and improved margins (adj. EBITDA margin 22%) underpin RELY's shift to profitability and robust forward outlook.

SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Remitly Global, Inc. (NASDAQ: RELY) (“Remitly”), a trusted provider of financial services that transcend borders, today announced that its management team will present at the following investor conferences:

Post-Earnings Virtual Webinar with Cantor
Date: Wednesday, May 13, 2026
Time: 1 p.m. Eastern Time / 10 a.m. Pacific Time
Ramsey El-Assal, Cantor research analyst, will host CEO Sebastian Gunningham and CFO Vikas Mehta for a question and answer session. Please reach out to Ramsey El-Assal at [email protected] or register here for access to the May 13 live webinar.

J.P. Morgan Global Technology, Media and Communications Conference, Boston
Date: Monday, May 18, 2026
Time: 11:05 a.m. Eastern Time / 8:05 a.m. Pacific Time
CEO Sebastian Gunningham and CFO Vikas Mehta will participate in a fireside chat at the J.P. Morgan Global Technology, Media and Communications Conference. The fireside chat will be webcast live from Remitly’s investor relations website at https://ir.remitly.com/. After the presentation, a replay of the event will be available on the investor relations website.

Bernstein Strategic Decisions Conference, New York City
Date: Wednesday, May 27, 2026

Bank of America Global Technology Conference, San Francisco
Date: Thursday, June 4, 2026

Bank of America Global Research C-Suite TMT Conference, London
Date: Wednesday, June 10, 2026
Time: 2:50 p.m. British Time / 9:50 a.m. Eastern Time / 6:50 a.m. Pacific Time
CFO Vikas Mehta will participate in a fireside chat at the Bank of America Global Research C-Suite TMT Conference. The fireside chat will be webcast live from Remitly’s investor relations website at https://ir.remitly.com/. After the presentation, a replay of the event will be available on the investor relations website.

About Remitly
Remitly is a trusted provider of financial services that transcend borders. With a footprint spanning more than 175 countries, Remitly has built one of the world’s leading global money movement platforms, trusted by millions of customers. Remitly continues to evolve beyond a remittance company into a diversified, cross-border financial services provider, serving both consumers and businesses across a growing set of use cases.

Investor Relations Contact:
[email protected]

Media Inquiries:
[email protected]

SOURCE Remitly Global, Inc.

Mobile payments are transforming checkout worldwide, and companies like INTU, RELY, WEX and PAY are positioning to ride the next wave of digital commerce growth.

Remitly Global, Inc. (RELY - Free Report) closed the last trading session at $20.87, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $26.75 indicates a 28.2% upside potential.

The mean estimate comprises 10 short-term price targets with a standard deviation of $3.57. While the lowest estimate of $20.00 indicates a 4.2% decline from the current price level, the most optimistic analyst expects the stock to surge 58.1% to reach $33.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

But, for RELY, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Here's Why There Could be Plenty of Upside Left in RELYAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 30.7%, as three estimates have moved higher compared to no negative revision.

Moreover, RELY currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much RELY could gain, the direction of price movement it implies does appear to be a good guide.

Many investors today are trying to fight what's colloquially known as FOMO, or fear of missing out. Stocks like Micron Technology are up close to 10-fold during the past 12 months, driving the S&P 500 Index to new heights, while leaving many other stocks -- possibly in your portfolio -- in the dust. It is hard to watch others make boatloads of money, but it is in this moment that disciplined, contrarians can make investments that set them up for success through the market cycle.

I would never promise that a stock can go up 10-fold within a year. If anyone tries to sell you this story, run the other way. What you can find are stocks with the potential to deliver multibagger returns over a decade, if you buy at a low price when the business is primed for growth. Here are two small-cap stocks that could turn a $5,000 investment into $50,000 over the course of a decade.

Image source: Getty Images.

1. Remitly's market share gains First up is Remitly Global (RELY +1.44%). The company, with a market cap of just $4.2 billion, is attacking the global remittance market and gaining market share rapidly. It is doing so by building an easy-to-use mobile application for senders with many pick-up options for recipients around the globe, alongside relatively low fees and new products layered on top.

Today's Change

(

1.44

%) $

0.27

Current Price

$

19.06

Remitly's send volume increased 37% year over year last quarter to $22 billion, while revenue rose 25% to $453 million. The company has continued to attract individuals in its core send markets, from the U. S. to Mexico and India, while also expanding rapidly into new areas and offering remittance services for small businesses.

These expansion efforts are broadening Remitly's total addressable market, which should bring revenue growth for years to come. At the same time, Remitly's profit margins and widening, posting a net income margin of 11% last quarter. Combine these two factors with Remitly's small market cap, and the stock has huge multibagger potential.

2. Wix's dirt cheap valuation Wix (WIX +0.14%) is a stock deemed an artificial intelligence (AI) loser in a big way. The company founded its business on no-code website building, which Wall Street believes will be disrupted by the artificial intelligence (AI) models like Anthropic's Claude.

Today's Change

(

0.14

%) $

0.06

Current Price

$

44.13

This has not yet shown up in Wix's financial performance. Last quarter, revenue rose 14% year over year to $541 million, with solid growth across all product segments. Importantly, its recent acquisition of Base44 -- an AI-powered mobile app builder -- has just crossed $150 million in annual recurring revenue (ARR). A year ago at this time, Base44 was generating almost no revenue.

It is this explosion in revenue that should have investors thinking Wix is a potential AI winner, not loser. On last year's conference call, management discussed how the company has already trained its own language model for its AI-powered website builder called Wix Harmony, which is seeing increased usage among customers. With a large data set from its long history as a website-building platform, Wix has the opportunity to build the best AI website creation tool as well.

Right now, Wix is not profitable on a GAAP (generally accepted accounting principles) basis due to recent heavy investments in growth, including two major NFL game ads. However, it trades at a market cap of just $2.2 billion, while revenue is $2 billion. If it can keep growing at a double-digit percentage rate and see a recovery in its profit profile as the AI boom matures, Wix stock has great multibagger potential.

RELY Revenue (TTM) data by YCharts

Why do both stocks have multibagger potential? Finding potential multibagger stocks doesn't require chasing the hottest names like Micron Technology after they have already soared. You want to find stocks with small market caps, a long growth runway, and a low starting valuation.

That describes both Remitly Global and Wix perfectly, and it's why they should make perfect additions to any investor's portfolio today.